Status:
COMPLETED
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Acquired Bleeding Disorder
Intracerebral Haemorrhage
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleedin...
Eligibility Criteria
Inclusion
- Spontaneous intracranial haemorrhage (ICH) within 3 hours after first symptom
Exclusion
- Patients with secondary ICH
- Pre-existing disability
- Haemophilia
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2004
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00426803
Start Date
August 1 2002
End Date
June 1 2004
Last Update
January 18 2017
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Melbourne, Australia, VIC 3052
2
Novo Nordisk Investigational Site
Graz, Austria, A-8036
3
Novo Nordisk Investigational Site
Antwerp, Belgium, 2020
4
Novo Nordisk Investigational Site
Calgary, Canada, AB T2N 2T9